Surgical Outcomes Following Neoadjuvant‐Targeted Therapy for Advanced Differentiated Thyroid Cancer—Real‐World Data
Neoadjuvant TKIs may improve the surgical outcomes of patients with advanced DTC. Decision-guided radiological and blood-based surrogate biomarkers, such as TSH, can assist in evaluating treatment response and guide decisions regarding treatment duration and extent of surgical resection.
Authors
- Shahaf Shilo (ORCID: https://orcid.org/0000-0001-6474-7435)
- Genady Shendler
- Alexandra Dorman (ORCID: https://orcid.org/0000-0002-4997-1743)
- Ben‐Zion Joshua (ORCID: https://orcid.org/0000-0002-2010-892X)
- Elena Izkhakov (ORCID: https://orcid.org/0000-0002-4742-878X)
- Inbar Finkel
- Orit Gutfeld
- Eran E. Alon (ORCID: https://orcid.org/0000-0002-2981-6092)
- Galit Avior (ORCID: https://orcid.org/0000-0002-6716-8671)
- Anton Warshavsky (ORCID: https://orcid.org/0000-0001-8163-5291)
- Eric Remer (ORCID: https://orcid.org/0000-0003-1897-7787)
- Lydia Furman
- Gilad Horowitz (ORCID: https://orcid.org/0000-0003-0719-3098)
- Nidal Muhanna (ORCID: https://orcid.org/0000-0002-3673-006X)
- Jobran Mansour
- Avi Khafif
Institutions
- Ben-Gurion University of the Negev (IL)
- Tel Aviv University (IL)
- Tel Aviv Sourasky Medical Center (IL)
- Sheba Medical Center (IL)
- Assuta Medical Center (IL)
- Barzilai Medical Center (IL)
- Temple University (US)
Publication Details
- Journal
- Clinical Endocrinology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1111/cen.70054
- Citations
- 1
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.29